TABLE 1.
Baseline Characteristics of the Study Cohort of 371 Acromegaly Patients Treated With SRS
| Factor | Total (%) |
|---|---|
| Age at SRS (mean ± SD [range], years) | 46.0 ± 13.9 (13.6-92) |
| Gender | |
| Male | 169 (45.6%) |
| Female | 202 (54.4%) |
| Prior surgical resection | 345 (93.0%) |
| Time interval from last resection to SRS (mean ± SD [range], months) | 30.7 ± 42.2 (1-300) |
| Prior EBRT | 20 (5.4%) |
| SRS indication | |
| Primary treatment | 26 (7.0%) |
| Residual tumor | 326 (87.9%) |
| Recurrent tumor | 19 (5.1%) |
| Endocrinopathy prior to SRS | 81 (21.8%) |
| Hypothyroid | 29 (7.8%) |
| Testosterone/Estrogen deficiency | 40 (10.8%) |
| Hypocortisolemia | 8 (2.2%) |
| Diabetes insipidus | 4 (1.1%) |
| Visual deficits prior to SRS | 47 (12.7%) |
| Visual field deficit | 42 (11.3%) |
| Diplopia | 5 (1.3%) |
| Medical therapy prior to SRS | 132 (35.6%) |
| Medical therapy held prior to SRS | 74 (56.1%)a |
| No visible tumor on MRI prior to SRS | 27 (7.3%) |
| Tumor volume (mean ± SD [range], cm3) | 2.5 ± 2.9 (0.1-21.1)b |
| Random serum GH prior to SRS (mean ± SD [range], ng/mL) | 12.6 ± 22.9 (0-173) |
| Serum IGF-1 prior to SRS (mean ± SD [range], ng/mL) | 699.0 ± 365.6 (65.3-2915) |
| Endocrine follow-up duration (mean ± SD [range], months) | 78.9 ± 52.2 (6.0-315) |
SD, standard deviation; SRS, stereotactic radiosurgery; EBRT, fractionated external beam radiation therapy; GH, growth hormone; IGF-1, insulin-like growth factor-1
aProportion of patients who were on medical therapy prior to SRS (n = 132).
bBased on data from 344 patients with visible tumor on pre-SRS MRI.